









市场行情
/
股票
/
nasdaq-cmps
/

Compass Pathways PLC

CMPS

4.630USD

+0.290+6.68%

交易中（美东）报价延迟15分钟

433.30M总市值

亏损市盈率 TTM



Compass Pathways PLC

4.630

+0.290+6.68%

概览公司财务

Compass Pathways plc 是一家总部位于英国的生物技术公司，致力于加速患者获得心理健康领域循证创新的途径。该公司致力于裸盖菇素治疗的开发，其中其研究性 COMP360 裸盖菇素与心理支持 COMP360 裸盖菇素治疗相结合使用。COMP360 是其专有的裸盖菇素配方，包括其药物级多晶型裸盖菇素，经过优化以提高稳定性和纯度。该公司的初始重点是难治性抑郁症 (TRD)，包括当前治疗模式无法充分满足的患者。该公司已启动其 III 期计划，评估其 COMP360 裸盖菇素在 TRD 中的治疗效果。此外，该公司正在开展 PTSD 和神经性厌食症的 II 期试验。它还为在严重未满足需求的领域开展由研究人员发起的 COMP360 裸盖菇素研究的研究机构提供支持。

公司简介

公司代码CMPS

公司名称Compass Pathways PLC

上市日期Sep 18, 2020

CEOMr. Kabir Nath

员工数量166

证券类型Depository Receipt

年结日Sep 18

公司地址3Rd Floor, 1 Ashley Road

城市ALTRINCHAM

上市交易所NASDAQ Global Select Consolidated

国家United Kingdom

邮编WA14 2DT

电话17166766461

网址https://compasspathways.com/

公司代码CMPS

上市日期Sep 18, 2020

CEOMr. Kabir Nath

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Robert McQuade, Ph.D.

Independent Director

1.59M

Mr. Thomas Lonngren

Independent Director

89.05K

Mr. Kabir Nath

Chief Executive Officer, Executive Director

29.07K

+944.11%

Mr. David Norton

Independent Director

20.36K

+17.06%

Dr. Annalisa M. Jenkins

Independent Director

19.48K

+17.97%

Ms. Teri Loxam

Chief Financial Officer

11.21K

-86.53%

Dr. Guy Goodwin

Chief Medical Officer

1.99K

Mr. Justin Gover

Director

Dr. Linda Mcgoldrick, Ph.D.

Independent Director

Ms. Daphne Karydas

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Robert McQuade, Ph.D.

Independent Director

1.59M

Mr. Thomas Lonngren

Independent Director

89.05K

Mr. Kabir Nath

Chief Executive Officer, Executive Director

29.07K

+944.11%

Mr. David Norton

Independent Director

20.36K

+17.06%

Dr. Annalisa M. Jenkins

Independent Director

19.48K

+17.97%

Ms. Teri Loxam

Chief Financial Officer

11.21K

-86.53%

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

Deep Track Capital LP

9.23%

Atai Life Sciences AG

7.20%

RTW Investments L.P.

5.77%

TCG Crossover Management, LLC

4.02%

Vivo Capital, LLC

3.50%

Other

70.27%

持股股东

占比

Deep Track Capital LP

9.23%

Atai Life Sciences AG

7.20%

RTW Investments L.P.

5.77%

TCG Crossover Management, LLC

4.02%

Vivo Capital, LLC

3.50%

Other

70.27%

股东类型

持股股东

占比

Hedge Fund

26.98%

Investment Advisor

11.34%

Investment Advisor/Hedge Fund

10.33%

Corporation

7.38%

Individual Investor

6.26%

Venture Capital

6.06%

Research Firm

1.05%

Endowment Fund

0.23%

Bank and Trust

0.05%

Other

30.32%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

277

64.91M

69.37%

+3.93M

2025Q1

287

65.16M

70.41%

+4.19M

2024Q4

278

44.23M

47.77%

-10.96M

2024Q3

271

50.07M

70.05%

-2.63M

2024Q2

274

48.30M

70.14%

-3.09M

2024Q1

276

47.45M

68.96%

+541.76K

2023Q4

283

43.21M

76.55%

-1.53M

2023Q3

283

43.38M

82.47%

+3.50M

2023Q2

280

29.35M

64.55%

-6.45M

2023Q1

287

29.33M

69.18%

+3.80M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Deep Track Capital LP

8.86M

9.47%

Mar 31, 2025

Atai Life Sciences AG

6.91M

7.38%

Mar 05, 2025

RTW Investments L.P.

5.54M

5.92%

+2.44M

+78.71%

Mar 31, 2025

TCG Crossover Management, LLC

3.86M

4.12%

Mar 31, 2025

Vivo Capital, LLC

3.36M

3.59%

+1.75M

+109.10%

Mar 31, 2025

Nantahala Capital Management, LLC

2.83M

3.02%

+1.83M

+182.92%

Mar 31, 2025

Millennium Management LLC

2.77M

2.96%

-639.93K

-18.75%

Mar 31, 2025

Goldsmith (George Jay)

2.05M

2.19%

-129.33K

-5.93%

Mar 31, 2025

Malievskaia (Ekaterina)

2.03M

2.17%

-149.38K

-6.86%

Mar 31, 2025

Logos Global Management LP

2.00M

2.14%

+2.00M

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

AdvisorShares Psychedelics ETF

7.05%

Virtus LifeSci Biotech Clinical Trials ETF

0.56%

ARK Genomic Revolution ETF

0.44%

ALPS Medical Breakthroughs ETF

0.18%

Invesco Nasdaq Biotechnology ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.03%

iShares Biotechnology ETF

0.02%

SPDR S&P International Small Cap ETF

0.01%

Putnam Sustainable Future ETF

Blueprint Chesapeake Multi-Asset Trend ETF

AdvisorShares Psychedelics ETF

占比7.05%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.56%

ARK Genomic Revolution ETF

占比0.44%

ALPS Medical Breakthroughs ETF

占比0.18%

Invesco Nasdaq Biotechnology ETF

占比0.03%

ProShares Ultra Nasdaq Biotechnology

占比0.03%

iShares Biotechnology ETF

占比0.02%

SPDR S&P International Small Cap ETF

占比0.01%

Putnam Sustainable Future ETF

占比0%

Blueprint Chesapeake Multi-Asset Trend ETF

占比0%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

KeyAI

